SCHEMBL6682687

SCHEMBL6682687

COc1cccc(CNC(=O)C2=Nc3c(n(C)c(=O)n(Cc4ccccc4)c3=O)NC2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
TP53 P04637 4/20 0.45
RXFP1 Q9HBX9 2/20 0.45
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
ROCK2 O75116 2/20 0.44
ENPP2 Q13822 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MMP13 P45452 2/20 0.43
HTT P42858 1/20 0.43
TRPA1 O75762 1/20 0.43
RAB9A P51151 1/20 0.43
NR3C2 P08235 1/20 0.43
TOP2A P11388 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6662760 0.86 THRB (0.44) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL6661861 0.80 ADORA3 (0.45) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL6685134 0.76 MAPT (0.49) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL7120749 0.75 MAPT (0.46) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL6474162 0.74 MAPT (0.56) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL6680234 0.73 MAPT (0.48) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL6683329 0.73 MAPT (0.47) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL7120798 0.73 MAPT (0.49) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL6684431 0.72 KMT2A (0.49) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL6664200 0.72 MAPT (0.47) MAPTTP53RXFP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 MAPT 1473/4885TP53 2986/4885RXFP1 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.